Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 403
Selected: 0
NCT IDTitle
NCT04578106Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
NCT00495547SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome
NCT01384838Exercise Training in Postmenopausal Patients With Breast Cancer
NCT01524679Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen
NCT01066689Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
NCT05038657Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).
NCT04363853Tocilizumab Treatment in Patients With COVID-19
NCT00476996A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
NCT02569736Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
NCT01565200HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
NCT04984811NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NCT01306409Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)
NCT02012634Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
NCT05529524Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)
NCT01745965A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
NCT01259856Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
NCT00203606Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C
NCT00440167Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine
NCT00484328Ribavirin, Its Dosing Regime
NCT03784599T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
NCT04497285Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer
NCT00483405Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
NCT00273767Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB
NCT00973609Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)
NCT00223301Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis
NCT02914470Carboplatin-cyclophosphamide Combined With Atezolizumab
NCT01523340A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
NCT01259817Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
NCT05293015NP-Supported Multidisciplinary Diabetes Management During Perioperative Period
NCT00612586Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
NCT00205556Effect of Increased Convective Clearance by On-Line Hemodiafiltration on All Cause Mortality in Chronic Hemodialysis Patients
NCT05802836Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab
NCT05798312Randomized and Multicenter Study to Evaluate a Customizable Support Breast Cancer Material
NCT03046381Tocilizumab in Patients With Schnitzler's Syndrome
NCT04770272Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy
NCT00374036Metastatic Gastric Cancer FFCD 03-07
NCT06634225Use of Inertial Units in Patient With Multiple Sclerosis (IMUSEP)
NCT00316420Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
NCT05300282Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
NCT03385668Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies
NCT00262717Can Resistance Enhance Selection of Treatment? (CREST)
NCT05825261Exploring Novel Biomarkers for Emphysema Detection
NCT00275132Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT04059081A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment
NCT00730769Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
NCT00738829Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
NCT00335595Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients
NCT04759248Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer
NCT04400474Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
NCT01660776BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology